Please cite this article in press Juby Johnson et al., A Correlation Between NAFLD And T2DM, Indo Am. J. P. Sci, 2024; 11 (01).

1. M. Hu, F. Phan, O. Bourron, P. Ferré, F. Foufelle, Steatosis and NASH in type 2 diabetes, Biochimie (2017), doi: 10.1016/j.biochi.2017.10.019.
2. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
3. S.Singh,A.M.Allen,Z.Wang,L.J.Prokop,M.H.Murad,and R. Loomba, “Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta- analysis of paired-biopsy studies, ” Clinical Gastroenterology and Hepatology, vol. 13, no. 4, pp. 643–654, 2015.
4. Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, and M. Wymer, “Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes,” Hepatology, vol. 64, no. 1, pp. 73–84, 2016.
5. C. D. Williams, J. Stengel, M. I. Asike et al., “Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohe- patitis among a largely middle-aged population utilising ultrasound and liver biopsy: a prospective study,” Gastroenterology, vol. 140, no. 1, pp. 124–131, 2011.
6. D. Kim, A. Touros, and W. R. Kim, “ Nonalcoholic fatty liver disease and metabolic syndrome,” Clinics in Liver Disease, vol. 22, no. 1, pp. 133–140, 2018.
7. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212–8.
8. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132–8.
9. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2: 262–5.
10. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846–54. 11.Angelico F, Del DA, Conti R, Franciosio S, Feole K, Fiorello S et al. Insulin resistance, the metabolic syndrome and non-alcoholic fatty liver disease. J Clin Endocrinol Metabolism 2005; 90: 1578– 82.
12. Kelly DE, McKolanis TM, Hegasi RA, Kuller LH, Kalhan SC. Fatty liver in type-2 diabetes mellitus, relation to regional adiposity, fatty acids and insulin resistance. Am J Physiol Endocrinol Metab 2003; 285: 906 – 16.
13. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221 – 31. doi: 10.1056/NEJMra011775.
14. Yamane R, Yoshioka K, Hayashi K, Shimizu Y, Ito Y, Matsushita K, et al. Prevalence of nonalcoholic fatty liver disease and its association with age in patients with type 2 diabetes mellitus. World J Hepatol 2022;14:1226. doi: 10.4254/wjh.v14. i6.1226.
15. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 2022;10:284–96. doi: 10.1016/ S2213- 8587(22)00003-1.[4] Dharmalingam M, Yamasand
16. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–10.
17. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab.2013;98:483–95.
18. Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver International. 2011 May;31(5):700-6.
19. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver international. 2009 Jan;29(1):113-9.
20. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133:496–506.
21. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008;31:165–9.
22. Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, Hardies J, Cusi K. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes care. 2012 Apr 1;35(4):873-8.
23.146. Badman, M. K. & Flier, J. S. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 132, 2103–2115 (2007).
24. Shoelson, S. E., Herrero, L. & Naaz, A. Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169–2180 (2007).
25. GagginiM,MorelliM,BuzzigoliE,etal.Non-alcoholicfattyliver disease (NAFLD) and its connection with insulin resistance, dys- lipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544–60.
26. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270–87.
27. Yki-Jarvinen, H. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.Dig.Dis. 28, 203–209 (2010).
28. Canfora EE, Meex RC, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD andT2DM. Nature Reviews Endocrinology. 2019 May;15(5):261-73.
29. Badman, M. K. & Flier, J. S. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 132, 2103–2115 (2007).
30. Shoelson, S. E., Herrero, L. & Naaz, A. Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169–2m
31. Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10:645–55
32. Wilmot EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ, et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia. 2012;55:2895–905
33. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–44
34. Neel BA, Sargis RM. The paradox of progress: environmental disruption of metabolism and the diabetes epidemic. Diabetes. 2011;60:1838–48.
35. Snowling NJ, Hopkins WG. Effects of different modes of exer- cise training on glucose control and risk factors for complica- tions in type 2 diabetic patients: a meta-analysis. Diabetes Care. 2006;29:2518-2527.
36. Ryu S, Chang Y, Jung HS, et al. relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J. Hepatol. 2015;63:1229-12
37. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.
38. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the Amer- ican Association for the Study of LiverDiseases. Hepatology 2018;67:328–357
39. Stefan N, Ha ring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabejtes Endocrinol 2019;7:313–324
40. Bril F, Biernacki DM, Kalavalapalli S, et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2019;42:1481– 1488
41. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in sub- jects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297–2307
42. Aithal GP, Thomas JA, Kaye PV, et al. Ran- domized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic stea- tohepatitis. Gastroenterology 2008;135:1176– 1184
43. Sanyal AJ, Chalasani N, Kowdley KV, et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675–1685
44. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with non- alcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 2016;165:305–315